Investor Presentation Q1 2018
Investor Presentation
First three months of 2018
Slide 23
Sales growth driven by the diabetes pandemic
Novo Nordisk reported quarterly sales
Reported sales split by product segments for
first three months of 2018
by therapy
Diabetes and obesity
Haemophilia²
Long-acting insulin
NorditropinⓇ
Other
Human insulin
Growth disorders
Reported sales
CAGR¹: 9.8%
DKK
billion
35
30
25
-2.9%
20
5.4%
15
5.7%
10
11.2%
Premix insulin
GLP-1
Fast-acting insulin
Other diabetes and obesity
Haemophilia
Other biopharmaceuticals
5%
9%
1% 18%
7%
10%
10
5
0
Q1
2008
1 CAGR for 10-year period
2 Haemophilia comprises NovoSeven®, NovoThirteenⓇ, NovoEight® and Refixia®
changing
diabetes
Q1
2018
22%
18%
9%
Sales of DKK 26.9 billion (5%)
novo nordiskView entire presentation